# Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects

> **NCT00606359** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 62 (actual)

## Conditions studied

- Influenza
- Orthomyxoviridae Infections

## Interventions

- **BIOLOGICAL:** Inactivated, split-virion influenza virus
- **BIOLOGICAL:** Inactivated, split-virion influenza virus

## Key facts

- **NCT ID:** NCT00606359
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606359, "Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00606359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*